Home › Stocks › TMED

TMED — T ROWE PRICE EXCHANGE-TRADED

Reported value held$205.03K
Funds holding (latest)2
Sector—
Funds holding (Q2 2026)1
Institutional value$203.48K · 5.96K sh
New / Add / Cut / Exit0 / 0 / 1 / 0
Top-5 / Top-10 concentration100.0% / 100.0%
Institutional holdings change Reducing -91.1% (-60.70K sh)
Institutional value change Down -89.4%

As of Q2 2026, 1 SEC-registered investment managers reported holding TMED (T ROWE PRICE EXCHANGE-TRADED) in their latest 13F filings, with a combined reported value of $203.48K across 5.96K shares. That is -91.1% by share count (-60.70K shares) versus the previous quarter, while reported value moved -89.4%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.

Compared with the prior quarter, 1 trimmed. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.

All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.

FundQuarterSharesValuePortfolio WeightChange
Citadel Advisors history Q2 2026 5.96K $203.48K 0.00% Reduce
UBS Group AG history Q4 2025 52 $1.55K 0.00% New

New Positions (Q2 2026)

No fund opened a new position this quarter.

Fully Exited (vs previous quarter)

No tracked fund fully exited this quarter.

Fund Position History — shares by quarter (top 2 funds)

FundQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Citadel Advisors 9.59K 29.77K 27.60K 66.66K 5.96K
UBS Group AG — — 52 — —

Download holders (CSV)